No statistically significant correlation was found between expression of CAV1, CAV2 and CAV1 and/or CAV2 and patient outcome (BCSS and DFS) in the group of chemotherapy-treated patients and when only patients with triple-negative breast cancers were analysed. This evidence concerns the gene CAV1 and triple-negative breast carcinoma.